Garuda Therapeutics develops proprietary hematopoietic stem cell (HSC) therapies designed to enable durable, self‑renewing, HLA‑compatible and transgene‑free blood stem cells that can be made available immediately for patients. The company is led by CEO Avanish Vellanki and is based in Cambridge, MA. Its technology focuses on producing HSCs that are human leukocyte antigen (HLA) compatible and transgene‑free. Garuda said its platform yields self‑renewing blood stem cells intended to be durable in patients. The company raised $50M in a Series A‑1 financing to advance its development. Garuda plans to use the proceeds to advance its pipeline into the clinic, assemble an experienced team, scale in‑house manufacturing, and support general operating activities. Garuda Therapeutics is developing an off-the-shelf platform to generate self-renewing blood stem cells intended to eliminate dependence on donor or patient cells for transplants. The company aims to provide consistent, durable, HLA-compatible and transgene-free blood stem cell therapies that could address more than 120 diseases. Garuda is advancing programs toward the clinic for hematological diseases and is developing an HSC-derived off-the-shelf durable immune cell program for oncology indications. It is also working on HLA-matched pluripotent stem cells to broaden patient eligibility and access to cellular therapies. The company is based in Cambridge, Mass., and highlights scalability, durability, and broader accessibility as core objectives. Garuda’s leadership includes Co-Founder and CEO Dhvanit Shah, Ph.D., and the company recently added Raymond J. Kelleher, M.D., Ph.D., to its board. Garuda Therapeutics is building an off-the-shelf platform to generate self-renewing, HLA-compatible, transgene-free blood stem cells intended to provide rapid and consistent access to durable stem cell therapies. The platform aims to remove reliance on donor or patient cells, potentially addressing limitations in scale, timeliness, durability, quality and safety of current blood stem cell material. Garuda positions its technology to broaden access to curative bone marrow–style therapies and to reduce match barriers faced by racial minority and mixed-race patients. Its pipeline targets hematologic malignancies, sickle cell disease, β-thalassemia, bone marrow failure diseases and other indications. Garuda launched with an oversubscribed $72 million Series A financing. The company was founded by Dhvanit Shah, Ph.D., and includes scientific founders and advisors such as David Scadden, M.D., and Sean Morrison, Ph.D.

Total raised

$184M

Funding rounds

3

Latest round

Series A

Latest activity

Mar 2025